AIC Conducts Joint Study with Grifols to Improve Quality of SCIG Treatment for PID Patients
Advanced Infusion Care (AIC), a division of AIS Healthcare, has joined forces with Grifols, a global leader in plasma-derived and transfusion medicines, to research the effects of subcutaneous immunoglobulin (SCIG) products on individuals living with primary immune deficiencies (PID), reports Yahoo Finance.
During the three-month study, 60 patients beginning SCIG therapy will be monitored to identify any differences in patient experience and satisfaction with immunoglobulin treatments. This study, known as the Satisfaction and Outcomes in Primary Immune Deficiency Patients Study (SOPID), aims to provide insight to healthcare professionals for the best possible therapy options for patients with PID, as per the article.
PID affects around 500,000 individuals in the US, according to the National Institute of Allergy and Infectious Diseases. SCIG therapy is seen as an effective method to prevent infections due to its low incidence of adverse effects and ease of administration.
Jud Hall, President of AIC, expressed pride in collaborating with Grifols to conduct a study that will provide valuable information on improving treatment for individuals with primary immune deficiencies. Grifols, a reputable producer of innovative and high-quality medicines for chronic and rare diseases, also emphasizes the commitment to helping patients receive high-quality care, as noted Hall.
A recent case study in the National Home Infusion Association’s (NHIA) Infusion Journal highlighted AIC’s model of assessing unique patient circumstances to guide decisions for immunoglobulin treatment, underscoring the importance of patient preference when choosing therapy options.
The SOPID study, in collaboration with AIC’s extensive clinical care network, aims to provide insights that will benefit all PID patients. AIC operates a network of 200 nurses in 40 states, offering patient-specific, in-home infusion services, including SCIG treatment.
Founded in 2008, AIS Healthcare and Grifols both have long histories of providing targeted drug delivery and infusion care to people with immune deficiencies. AIC has been offering Grifols infusion therapy Xembify® to PID patients since 2019, emphasizing high-quality care and offering a dedicated team of medical and healthcare professionals to provide support throughout the treatment process.
The goal of the SOPID study is to improve the quality of life for individuals with PID providing insights into how different SCIG products can cater to patient needs, underlining the commitment of AIC and Grifols to patients’ wellbeing.
There are tags and further details provided in the article within TechTimes, but the content shared in this summary has helped highlight the recent joint study between AIC and Grifols to improve the quality of SCIG treatment for patients with PID.